

2015 MEDIA KIT

PRINT | WEB | MOBILE

haymarketoncology

Building Knowledge Through Practical Information

Cancer Therapy
Advisor

OncologyNurseAdvisor

A new journal-sized publication that delivers the latest relevant clinical information straight to oncology health professionals every other month

CONTENT INCLUDES

- Cancer treatment regimens
- Concise *MPR* drug monographs organized by tumor type
- Featured drugs and pipeline information
- CME-accredited activity
- Expert review, interviews, commentary, research and analysis
- Desk-sized format for examining room or office placement

PRINT FREQUENCY

Every other month

PRINT CIRCULATION

Hematologists/Oncologists and other MD Specialties	13,652*
PA/NPs	835
Oncology Nurses	4,393
PharmDs in Hospital Settings	1,617
TOTAL	20,497

*Includes all AMA file Hematologists, Oncologists, Hematologist/Oncologists, Gynecologic Oncologists, Musculoskeletal Oncologists, Pediatric Oncologists, Surgical Oncologists, and IMs with a sub-specialty in Oncology.

AUDIENCE PENETRATION

- 85% recall receiving the premier issue of CTA¹
- Latest News, CME and Treatment Regimens rank as the top 3 sections¹
- 63% will save their issue for reference, share it with a colleague or display it in their office/institution¹

1. CTA September 2014 Print User Survey

“The new print version of *Cancer Therapy Advisor* took the most useful content from *MPR Hematology & Oncology*, their concise cancer treatment regimens and oncology drug monographs and paired them with CME, expert editorials and trending oncology articles making this a truly valuable oncology clinician information resource.”

Barbara Ann Burtress, MD
Clinical Research Program Leader,
Head and Neck Cancers Program
Yale Cancer Center
New Haven, CT



PRINT: Black & White Rates

	1 PAGE
1 ×	\$6,210
6 ×	\$6,053
12 ×	\$5,910
24 ×	\$5,753
36 ×	\$5,633
48 ×	\$5,565
60 ×	\$5,520
72 ×	\$5,445
96 ×	\$5,348
120 ×	\$5,310
150 ×	\$5,250

PRINT: 4-Color charge \$2,457

POSITION CHARGES

Cover 2 and Facing Page	25%
TOC	15%
Cover 3	50%
Cover 4	50%

VALUE ADDED LINE ADS

Ask about line ad section takeovers

COMBINATION DISCOUNT

Advertise in both *Cancer Therapy Advisor* and *Oncology Nurse Advisor* and receive a 10% discount (Ads must be for the same product; discount applies to ads of equal or smaller size).

CORPORATE DISCOUNT

Individual pharmaceutical companies and their subsidiaries may qualify for this additional corporate discount, based on their total gross spending in 2015.

The amount of the discount when combining total gross spending for *Cancer Therapy Advisor*, *The Clinical Advisor*, all MPR titles, *McKnight's Long Term Care News*, *Assisted Living*, *Renal & Urology News*, *Oncology Nurse Advisor* using 2015 rates are calculated after combo, continuity and special discounts are applied.

Gross Spend Levels:

\$250,000 - \$750,000 = 2%
 \$750,001 - \$1,500,000 = 3%
 \$1,500,001 - \$2,500,000 = 5%
 \$2,500,001 - \$3,500,000 = 7%
 \$3,500,001+ = 10%

CLOSING DATES 2015

ISSUE	AD CLOSING	MATERIALS
January/February	December 8	December 10
March/April	February 6	February 11
May/June	April 10	April 14
July/August	June 4	June 9
September/October	August 4	August 7
November/ December	October 13	October 16

PRODUCTION SPECS

PRODUCTION CONTACT: cta.prodmngr@haymarketmedia.com

PRINTER: RR Donnelley, 1600 N. Main Street, Pontiac, IL 61764

PRODUCTION SPECIFICATIONS

Inserts:

- Trim size of the publication is 7 ¾" × 10 ½"
- Maximum finished insert size is 8" × 10 ¾"

SHIPPING

Inserts are to be in cartons on skid. Ship with publication name, issue date, and insert quantity clearly marked. Each issue packed separately.

Delivery Address:

RR Donnelley, 1600 N. Main Street, Pontiac, IL 61764

Attn: Mary Sue Patterson for CTA

QUANTITY: 20,500

INSERT DUE DATE: 25th of the month prior to publication

ADVERTISING

- Final trim size must be 7 ¾" × 10 ½"
- Live area: 7.25" x 10"
- Bleeds must extend ¼" past trim lines all around. Thus, bleeds on all four sides mean that the bleeds extend out to 8" × 10 ¾"
- Live area for line ads: 6.875" x .75"

MECHANICAL SPECIFICATIONS

- Hold Live Matter: ¼" from trim
- Type of Binding: Perfect bound
- Material Policy: Reproduction material will be held 12 months from date of last insertion and then destroyed.

DIGITAL FILES

- Include standard trim, bleed, and center marks in all separations and outside trim (no marks included in the "live" image area)
- Please supply PDFs as single pages. Export settings can be found here: <http://www.rrdonnelley.com/prepress/prepare/indesign/export-pdf.aspx>
- A CD ROM and contact color proof of the file should also be sent to: **Krassi Varbanov**
 Haymarket Media Inc., 114 West 26th Street, 4th Fl., New York, NY 10001

A comprehensive online resource that offers oncology healthcare professionals a wide range of practical knowledge

CONTENT INCLUDES

- Cancer treatment regimens
- Concise MPR drug monographs organized by tumor type
- Relevant clinical charts and medical calculators
- Extensive clinical trial information
- Expert reviews
- Oncology-specific resources for patient-care

AUDIENCE PENETRATION

- Greater than 190,000 page views per month¹
- Over 90,000 unique visitors per month¹
- 28,000 plus newsletter opt-ins²
- 61% of CTA users use the site at least once per week³

HOW DOES THE AUDIENCE FEEL ABOUT CANCERTHERAPYADVISOR.COM?


- Over 60% of users access CTA at least once a week³
- 9 out of 10 users find CTA useful for their clinical practice⁴
- 9 out of 10 users find CTA newsletters useful/informative⁴
- Core content (cancer treatment regimens, concise drug information, latest oncology news) is rated very valuable⁴

1. Omniture, June 2014, CTA Monthly Report
2. Silverpop, June 2014, CTA Monthly Report
3. CTA July 2014 Online User Survey
4. CTA July 2012 Online User Survey



“ In addition to being an easy to use, one-stop resource for chemotherapy regimens and drug information, CancerTherapyAdvisor.com is also a valuable tool for oncologists who treat many different types of cancers. The news stories, feature articles, and expert commentary are clinically relevant and well organized, and deliver up-to-date information to the entire oncology community. ”

E. David Crawford, MD
Professor of Surgery/
Urology/Radiation
Oncology
Head Urologic
Oncology
E. David Crawford
Endowed Chair in
Urologic Oncology
University of Colorado,
Denver Aurora, CO



2015 DIGITAL RATES


WEB OPPORTUNITIES	CPM	PRICE/MOS
Run of Site (ROS)	\$96	\$2,400
Specialty-Targeted ROS	\$180	Contingent Upon List Size
List-Match-Targeted ROS	\$245	Contingent Upon List Size
Content Posting	Flat Rate	Video: \$1,630 / Static: \$1,087
Section Takeover	Flat Rate	\$5,000*
Homepage Road Block	Flat Rate	\$870/day**
Prestitial	Flat Rate	\$870/day**
ROS Text Ad	Flat Rate	\$543
Microsite	Flat Rate	\$65,000/yeart
Conference Coverage Sponsorship	Flat Rate	\$8,150/conference
Virtual Conference Exhibit Booth	Flat Rate	Silver Sponsor: \$8,500 / Gold Sponsor: \$12,500 / Platinum Sponsor: \$19,500
EMAIL OPPORTUNITIES		
Editorial Newsletter		Banners: \$2,500 (Buy 3, receive \$500 discount per drop / Buy 6, receive \$1,000 discount per drop) Text Ads: \$500
Specialty Targeted Newsletter		\$2,500 (Buy 3, receive \$500 discount per drop / Buy 6, receive \$1,000 discount per drop)
Spotlight Newsletter		\$3,500 (Buy 3, receive \$500 discount per drop / Buy 6, receive \$1,000 discount per drop)
Custom Email Blast		\$0.79/name + \$1,500 set-up
MOBILE OPPORTUNITIES		
Run of App (ROA)	\$96	\$1,440
Specialty-Targeted ROA	\$180	Contingent Upon List Size
List-Match-Targeted ROA	\$245	Contingent Upon List Size
Content Posting	Flat Rate	Video: \$1,630 / Static: \$1,087
Section Takeover	Flat Rate	\$1,523
Drug Subsection Takeover	Flat Rate	\$1,035
Homepage Road Block	Flat Rate	\$870/day**
Sponsored News Release (i.e. Alert)	Flat Rate	\$25,000/send
Mobile Prestitial	Flat Rate	\$870/day**
Mobile Microsite	Flat Rate	\$65,000/yeart

* \$5,000 monthly cost has no impression max, or buy takeover for \$2,400 with impression cap at 5,000


** Limit 1 week/mo

† Development only; pricing may vary based on content provided and complexity of development required (pricing does not include traffic drivers)


Leader Board
728 × 90




Medium Rectangle
300 × 250



Half Page
300 × 600



Navigation Bar Ad
1000 × 30



Clinical updates and evidence-based information geared towards the oncology nurse and other cancer care providers

CONTENT INCLUDES

- Side-effect management
- Survivorship issues
- Patient education and navigation
- Safe handling and administration of medications
- Impact of genomics/genetics on cancer treatment
- Communication with patients, caregivers, and the cancer care team

PRINT FREQUENCY

Every other month



PRINT CIRCULATION

Oncology Nurse	16,859
Nurse Practitioner	2,986
Physician Assistant	1,422
Director of Nursing	2,363
TOTAL	23,630

AUDIENCE PENETRATION

- Over 76% read cover to cover or articles of interest and look through the remaining pages¹
- #3 ad page exposure ranking out of 14 publications reaching this audience¹

HOW DOES THE AUDIENCE FEEL ABOUT ONCOLOGY NURSE ADVISOR?

- 9 out of 10 readers find ONA offers high overall quality²
- 9 out of 10 readers find ONA provides practical, useful information²
- 9 out of 10 readers find ONA articles of high value for their specific need²

1. Kantar Media, Oncology Nursing, 2014 Readership Data
2. ONA Reader Survey, October 2010

“Oncology Nurse Advisor makes oncology issues practical and applicable to everyday cancer care. The focused article departments such as Ask the Pharmacist and Issues in Cancer Survivorship enhance the knowledge base of the oncology nurse, thus helping them to improve the treatment they provide to patients.”

Jia Conway,
DNP, FNP-BC,
AOCNP, NP-C
Cancer Care
Associates of York
York, Pennsylvania



PRINT: Black & White Rates

	1 PAGE	½ PAGE
1×	\$3,910	\$2,610
6×	\$3,850	\$2,520
12×	\$3,790	\$2,470
24×	\$3,670	\$2,400
36×	\$3,530	\$2,350
48×	\$3,410	\$2,280
60×	\$3,360	\$2,220
72×	\$3,280	\$2,160
96×	\$3,220	\$2,100
120×	\$3,160	\$2,020
150×	\$3,120	\$1,970

INSERTS: Charged at the page for page black & white rate

PRINT: 4-Color Charge \$2,190

POSITION CHARGES

Cover 2 and Facing Page	25%
TOC	15%
Cover 3	50%
Cover 4	50%

COMBINATION DISCOUNT

Advertise in both *Oncology Nurse Advisor* and *Cancer Therapy Advisor* and receive a 10% discount (Ads must be for the same product; discount applies to ads of equal or smaller size).

CORPORATE DISCOUNT

Individual pharmaceutical companies and their subsidiaries may qualify for this additional corporate discount, based on their total gross spending in 2015.

The amount of the discount when combining total gross spending for *Oncology Nurse Advisor*, *The Clinical Advisor*, all *MPR* titles, *McKnight's Long Term Care News*, *Assisted Living*, *Renal & Urology News*, *Cancer Therapy Advisor* using 2015 rates are calculated after combo, continuity and special discounts are applied.

Gross Spend Levels:

\$250,000 - \$750,000 = 2%
 \$750,001 - \$1,500,000 = 3%
 \$1,500,001 - \$2,500,000 = 5%
 \$2,500,001 - \$3,500,000 = 7%
 \$3,500,001+ = 10%

CLOSING DATES 2015

ISSUE	AD CLOSING	MATERIALS
January/February	January 15	January 22
March/April	March 13	March 20
May/June	May 15	May 22
July/August	July 15	July 22
September/October	September 14	September 21
November/December	November 17	November 24

PRODUCTION SPECS

PRODUCTION CONTACT: ona.prodmngr@haymarketmedia.com

PRINTER: RR Donnelley, 1600 N. Main Street, Pontiac, IL 61764

PRODUCTION SPECIFICATIONS

Inserts:

- Trim size of the publication is 7 ¾" × 10 ½"
- Maximum finished insert size is 8" × 10 ¾"

SHIPPING

Inserts are to be in cartons on skid. Ship with publication name, issue date, and insert quantity clearly marked. Each issue packed separately.

Delivery Address:

RR Donnelley, 1600 N. Main Street, Pontiac, IL 61764

Attn: Jim Dopler for ONA

QUANTITY: 26,500

INSERT DUE DATE: 1st of month of publication

ADVERTISING

- Final trim size must be 7 ¾" × 10 ½"
- Live area: 7.25" x 10"
- Bleeds must extend ¼" past trim lines all around. Thus, bleeds on all four sides mean that the bleeds extend out to 8" × 10 ¾"

MECHANICAL SPECIFICATIONS

- Hold Live Matter: ¼" from trim
- Type of Binding: Perfect bound
- Material Policy: Reproduction material will be held 12 months from date of last insertion and then destroyed.

DIGITAL FILES

- Include standard trim, bleed, and center marks in all separations and outside trim (no marks included in the "live" image area)
- Please supply PDFs as single pages. Export settings can be found here: <http://www.rrdonnelley.com/prepress/prepare/indesign/export-pdf.aspx>
- A CD ROM and contact color proof of the file should also be sent to: **Krassi Varbanov**
 Haymarket Media Inc., 114 West 26th Street, 4th Fl., New York, NY 10001

An online resource that provides oncology information that is timely, relevant, and applicable to current practice

CONTENT INCLUDES

- Electronic access to information that enables quality oncology care
- Daily reports from the recent literature
- Up-to-date drug information
- Patient information and fact sheets
- Point-of-care guides and tools
- Interactivity with oncology colleagues

AUDIENCE PENETRATION

- More than 149,000 page views and over 84,000 unique visitors per month¹
- 17,000 newsletter opt-ins²

HOW DOES THE AUDIENCE FEEL ABOUT ONCOLOGYNURSE ADVISOR.COM?

- 29% of visitors to ONA return in less than 1 day³
- 27% of visitors to ONA return in 1 to 7 days³

1. Omniture, June 2014, ONA Monthly Report
2. Silverpop, July 2014, ONA Monthly Report
3. Omniture, July-September 2014, ONA Frequency Report



“OncologyNurseAdvisor.com (ONA) offers current news and features about cancer treatment and patient care that can be readily applied to clinical practice. In addition, ONA provides oncology nurses with information they need and want to know, through outlets such as opinion polls and email blasts, which is easily accessible and always relevant.”

Rosemarie Tucci,
RN, MSN, AOCN
Manager,
Oncology Services
Lankenau
Medical Center
Wynnewood,
Pennsylvania




2015 DIGITAL RATES

WEB OPPORTUNITIES	CPM	PRICE/MOS
Run of Site (ROS)	\$65	\$1,625
List-Match-Targeted ROS	\$180	Contingent Upon List Size
Content Posting	Flat Rate	Video: \$1,035 / Static: \$518
Section Takeover	Flat Rate	\$2,175
Homepage Road Block	Flat Rate	\$870/day*
Prestitial	Flat Rate	\$870/day*
ROS Text Ad	Flat Rate	\$543
Microsite	Flat Rate	\$65,000/year**
Conference Coverage Sponsorship	Flat Rate	\$8,150/conference
Virtual Conference Exhibit Booth	Flat Rate	Silver Sponsor: \$8,500 / Gold Sponsor: \$12,500 / Platinum Sponsor: \$19,500
EMAIL OPPORTUNITIES		
Editorial Newsletter		Banners: \$2,500 (Buy 3, receive \$500 discount per drop / Buy 6, receive \$1,000 discount per drop) Text Ads: \$500
Spotlight Newsletter		\$2,500 (Buy 3, receive \$500 discount per drop / Buy 6, receive \$1,000 discount per drop)
Custom Email Blast		\$0.79/name + \$1,500 set-up
MOBILE OPPORTUNITIES		
Run of App (ROA)	\$65	\$975
List-Match-Targeted ROA	\$180	Contingent Upon List Size
Content Posting	Flat Rate	Video: \$1,035 / Static: \$518
Section Takeover	Flat Rate	\$875
Drug Subsection Takeover	Flat Rate	\$776
Homepage Road Block	Flat Rate	\$870/day*
Sponsored News Release (i.e. Alert)	Flat Rate	\$25,000/send
Mobile Prestitial	Flat Rate	\$870/day*
Mobile Microsite	Flat Rate	\$65,000/year**


* Limit 1 week/mo

** Development only; pricing may vary based on content provided and complexity of development required (pricing does not include traffic drivers)


Leader Board
728 × 90




Medium Rectangle
300 × 250



Half Page
300 × 600



Navigation Bar Ad
1000 × 30



CUSTOM SOLUTIONS

For more detailed information on each of these products and additional custom solutions, please contact the Publisher for a Fact Sheet

CO-PAY SUPPORT
Cancer Therapy Advisor
NANETS: Pancreatic New DNA Repair Gene Defects
FIRST REPORT Cancer Therapy Advisor Conference Coverage
ASCO 2014 2013 2012
ASH 2013 2012 2011
LATEST CONFERENCES
HPV-Targeted Adoptive T-cell Therapy Induces Regression in Metastatic Cervical Cancer

OncologyNurseAdvisor
NEW! ChemotherapyAdvisor.com
Featured Videos
FASLODEX® (flavestrant) Injection 500 mg Nursing Considerations
Maureen Major, APRN
Web Exclusives
Potentially reusable life often paper breast cancer receptors for years
New data on FASLODEX® (flavestrant) Injection 500 mg
First cycle of higher dose chemotherapy led to advanced high-dose chemotherapy, not the double-dose cycle of a lower-dose

KOL Video / Roundtable

Treatment of Ph+ CML
Advancing Science
Advancing Care
Future goals for Ph+ CML patients are being shaped by an actively evolving paradigm. Stay up to date with these interactive assets.
Explore the evolution of Ph+ CML care
Find out more about early therapies, important milestones, and the new era of advanced care
Learn more >
Optimize the evolution of the CML care
A guide to read and interpret the CML reports
Which is new video on the CML
Dr. Peter Serrhini discusses the importance of getting the most out of your CML reports
For information about a free trial of IQ-PCR, call MolecularIQ at 877-433-9379 or Genopix at 800-755-1605 and ask about GET IQ-PCR NOW. To learn more about Ph+ CML treatment options, click here.
NOVARTIS
Novartis Pharmaceuticals Corporation
East Hanover, NJ 07936-0001
© 2012 Novartis
810
T.000.100708

Microsite / Infosite

OncologyNurseAdvisor
FIRST REPORT Oncology Nurse Advisor Conference Coverage
ONS Annual Congress 2014 2013 2012
ASCO 2014
Disparities persist in cancer care
Does Early Integration of Palliative Care and Cancer Treatment Benefit Patients?
ONLINE ARTICLES
ONLINE NEWSLETTERS

First Report Live Conference Coverage

MPR Fact Pack
Understanding Myelofibrosis and the Role of JAK Inhibition
MPR Fact Pack
Myelofibrosis: An Overview
Understanding Janus Kinases
Clinical Safety and Efficacy
MPR Fact Pack
MYELOFIBROSIS: AN OVERVIEW
Epidemiology
Symptoms and Pathophysiology

Digital/Mobile Fact Pack

MPR Fact Pack
ADVANCEMENTS IN IMMUNOTHERAPY for the Treatment of Cancer
IMMUNE SYSTEMS ROLE IN CANCER
OF CANCER PATHOGENESIS
EVENTS OF TUMOR
TUMOR GROWTH REGULATION (THE 3E'S)
IMPACT OF DIMINISHED IMMUNE FUNCTION

MPR Fact Pack

CUSTOM SOLUTIONS

For more detailed information on each of these products and additional custom solutions, please contact the Publisher for a Fact Sheet

MPR
MONTHLY PRESCRIBING REFERENCE

Concise Consult

ONFI (clobazam)®
in the Adjunct Management of Seizures Associated with Lennox-Gastaut syndrome in patients 2 years of age or older

Healthcare Professionals

- Overview of Lennox-Gastaut syndrome
- Introducing ONFI
- ONFI Efficacy and Safety
- ONFI Free Trial Offer

Please see Important Safety Information on page 6 and ONFI Full Prescribing Information and Medication Guide.

MPR ConciseConsult®

Oncology Nurse Advisor

Update on Melanoma Treatment: SYLATRON™ (peginterferon alfa-2b) for injection, for subcutaneous use

MPR PRESCRIBING ALERT

SYLATRON™ (peginterferon alfa-2b) for injection, for subcutaneous use

MPR PRESCRIBING ALERT

SYLATRON™ (peginterferon alfa-2b) for injection, for subcutaneous use

Oncology Nurse Advisor

NEED RESOURCES?

HOME NEWS EDITORIALS CATEGORIES RESOURCES MULTIMEDIA BOOKS FOR PATIENTS

XTANDI® (enzalutamide) capsules—Practice and Patient Resources

PRACTICE RESOURCES

- PDR Prescribing Information
- Dosing Card
- Interactive Checkups
- Healthcare Professional Website

PATIENT RESOURCES

- Patient Education Leaflet
- Treatment Calendar
- Patient Prescribing Information
- Patient Website

Product Resource Center

When Letrozole or Anastrozole Fails, Prescribe AFINITOR Plus Ecdemestane

Double Inhibition

Double Median PFS

55% reduction in risk of progression or death

Apoptosis has been shown to be a pathway-specific disease—not a mutation-specific disease

Stéphane Aebi, MD

The discovery of the JAK2V617F mutation has greatly advanced our understanding of the pathogenesis of myeloproliferative neoplasms (MPNs) and other myeloid malignancies.

MPR PRESCRIBING ALERT

Important information about SYLATRON™ (peginterferon alfa-2b) for injection, for subcutaneous use

MPR.com

The right dose of information

Update on Melanoma Treatment

SYLATRON™ (peginterferon alfa-2b) for injection, for subcutaneous use

HIGHLIGHTS OF PRESCRIBING INFORMATION

INDICATIONS AND USAGE

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

DOSE FORMS AND STRENGTHS

HOW SUPPLIED

DESCRIPTION

For subcutaneous injection, SYLATRON is a pegylated recombinant human interferon alpha-2b (IFN-α2b) conjugated with a polyethylene glycol (PEG) polymer.

MPR Integrated Prescribing Alert

Chemotherapy

Virtual Cancer Congress

Real Care in Real Time

Virtual Cancer Congress

Virtual Cancer Congress

Virtual Conferences

MPRxPress Direct Mail & Email